These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 35832541)

  • 1. CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated
    Napolitano S; Martini G; Ciardiello D; Di Maio M; Normanno N; Avallone A; Martinelli E; Maiello E; Troiani T; Ciardiello F
    Front Oncol; 2022; 12():940523. PubMed ID: 35832541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial.
    Martinelli E; Martini G; Famiglietti V; Troiani T; Napolitano S; Pietrantonio F; Ciardiello D; Terminiello M; Borrelli C; Vitiello PP; De Braud F; Morano F; Avallone A; Normanno N; Nappi A; Maiello E; Latiano T; Falcone A; Cremolini C; Rossini D; Santabarbara G; Pinto C; Santini D; Cardone C; Zanaletti N; Di Liello A; Renato D; Esposito L; Marrone F; Ciardiello F
    JAMA Oncol; 2021 Oct; 7(10):1529-1535. PubMed ID: 34382998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials.
    Martini G; Ciardiello D; Famiglietti V; Rossini D; Antoniotti C; Troiani T; Napolitano S; Esposito L; Latiano TP; Maiello E; Del Re M; Lonardi S; Aprile G; Santini D; Masi G; Avallone A; Normanno N; Pietrantonio F; Pinto C; Ciardiello F; Cremolini C; Martinelli E
    Cancer Med; 2023 Apr; 12(8):9392-9400. PubMed ID: 36880426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer: A Nonrandomized Controlled Trial.
    Ciardiello D; Martinelli E; Troiani T; Mauri G; Rossini D; Martini G; Napolitano S; Famiglietti V; Del Tufo S; Masi G; Santini D; Avallone A; Pietrantonio F; Lonardi S; Di Maio M; Zampino MG; Fazio N; Bardelli A; Siena S; Cremolini C; Sartore-Bianchi A; Ciardiello F
    JAMA Netw Open; 2024 Apr; 7(4):e245635. PubMed ID: 38592721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab.
    Martini G; Ciardiello D; Dallio M; Famiglietti V; Esposito L; Corte CMD; Napolitano S; Fasano M; Gravina AG; Romano M; Loguercio C; Federico A; Maiello E; Tuccillo C; Morgillo F; Troiani T; Di Maio M; Martinelli E; Ciardiello F
    Int J Cancer; 2022 Aug; 151(3):473-480. PubMed ID: 35429341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival.
    Ciardiello D; Famiglietti V; Napolitano S; Esposito L; Pietrantonio F; Avallone A; Maiello E; Cremolini C; Troiani T; Martinelli E; Ciardiello F; Martini G
    Clin Colorectal Cancer; 2022 Jun; 21(2):141-148. PubMed ID: 35101346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
    Cremolini C; Rossini D; Dell'Aquila E; Lonardi S; Conca E; Del Re M; Busico A; Pietrantonio F; Danesi R; Aprile G; Tamburini E; Barone C; Masi G; Pantano F; Pucci F; Corsi DC; Pella N; Bergamo F; Rofi E; Barbara C; Falcone A; Santini D
    JAMA Oncol; 2019 Mar; 5(3):343-350. PubMed ID: 30476968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with
    Martini G; Ciardiello D; Napolitano S; Martinelli E; Troiani T; Latiano TP; Avallone A; Normanno N; Di Maio M; Maiello E; Ciardiello F
    Front Oncol; 2023; 13():1069370. PubMed ID: 36860319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skin Toxicity as Predictor of Survival in Refractory Patients with
    Ciardiello D; Famiglietti V; Napolitano S; Esposito L; Normanno N; Avallone A; Latiano T; Maiello E; Pietrantonio F; Cremolini C; Santabarbara G; Pinto C; Troiani T; Martinelli E; Ciardiello F; Martini G
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.
    Cremolini C; Antoniotti C; Lonardi S; Aprile G; Bergamo F; Masi G; Grande R; Tonini G; Mescoli C; Cardellino GG; Coltelli L; Salvatore L; Corsi DC; Lupi C; Gemma D; Ronzoni M; Dell'Aquila E; Marmorino F; Di Fabio F; Mancini ML; Marcucci L; Fontanini G; Zagonel V; Boni L; Falcone A
    JAMA Oncol; 2018 Apr; 4(4):529-536. PubMed ID: 29450468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer.
    Stein A; Simnica D; Schultheiß C; Scholz R; Tintelnot J; Gökkurt E; von Wenserski L; Willscher E; Paschold L; Sauer M; Lorenzen S; Riera-Knorrenschild J; Depenbusch R; Ettrich TJ; Dörfel S; Al-Batran SE; Karthaus M; Pelzer U; Waberer L; Hinke A; Bauer M; Massa C; Seliger B; Wickenhauser C; Bokemeyer C; Hegewisch-Becker S; Binder M
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34315821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II Single-Arm Study of Palbociclib and Cetuximab Rechallenge in Patients with KRAS/NRAS/BRAF Wild-Type Colorectal Cancer.
    Sorah JD; Moore DT; Reilley MJ; Salem ME; Triglianos T; Sanoff HK; McRee AJ; Lee MS
    Oncologist; 2022 Dec; 27(12):1006-e930. PubMed ID: 36288238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial.
    Izawa N; Masuishi T; Takahashi N; Shoji H; Yamamoto Y; Matsumoto T; Sugiyama K; Kajiwara T; Kawakami K; Aomatsu N; Kondoh C; Kawakami H; Takegawa N; Esaki T; Shimokawa M; Nishio K; Narita Y; Hara H; Sunakawa Y; Boku N; Moriwaki T; Eguchi Nakajima T; Muro K
    Target Oncol; 2023 May; 18(3):369-381. PubMed ID: 37148491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients.
    Moretto R; Rossini D; Capone I; Boccaccino A; Perrone F; Tamborini E; Masi G; Antoniotti C; Marmorino F; Conca V; Borelli B; Martignetti A; Pecora I; Simionato F; Cupini S; Ambrosini M; Manca P; Pietrantonio F; Falcone A; Cremolini C
    Clin Colorectal Cancer; 2021 Dec; 20(4):314-317. PubMed ID: 34364814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study.
    Xu X; Ai L; Hu K; Liang L; Lv M; Wang Y; Cui Y; Li W; Li Q; Yu S; Feng Y; Liu Q; Yang Y; Zhang J; Xu F; Yu Y; Liu T
    Nat Commun; 2024 Aug; 15(1):7255. PubMed ID: 39179622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial.
    Della Corte CM; Fasano M; Ciaramella V; Cimmino F; Cardnell R; Gay CM; Ramkumar K; Diao L; Di Liello R; Viscardi G; Famiglietti V; Ciardiello D; Martini G; Napolitano S; Tuccillo C; Troiani T; Martinelli E; Wang J; Byers L; Morgillo F; Ciardiello F
    J Exp Clin Cancer Res; 2022 Mar; 41(1):109. PubMed ID: 35346313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translational analysis and final efficacy of the AVETUX trial - Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer.
    Tintelnot J; Ristow I; Sauer M; Simnica D; Schultheiß C; Scholz R; Goekkurt E; von Wenserski L; Willscher E; Paschold L; Lorenzen S; Riera-Knorrenschild J; Depenbusch R; Ettrich TJ; Dörfel S; Al-Batran SE; Karthaus M; Pelzer U; Hinke A; Bauer M; Massa C; Seliger B; Wickenhauser C; Bokemeyer C; Hegewisch-Becker S; Binder M; Stein A
    Front Oncol; 2022; 12():993611. PubMed ID: 36605436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).
    Damato A; Iachetta F; Antonuzzo L; Nasti G; Bergamo F; Bordonaro R; Maiello E; Zaniboni A; Tonini G; Romagnani A; Berselli A; Normanno N; Pinto C
    BMC Cancer; 2020 Aug; 20(1):822. PubMed ID: 32867715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial.
    Taïeb J; Bouche O; André T; Le Malicot K; Laurent-Puig P; Bez J; Toullec C; Borg C; Randrian V; Evesque L; Corbinais S; Perrier H; Buecher B; Di Fiore F; Gallois C; Emile JF; Lepage C; Elhajbi F; Tougeron D;
    JAMA Oncol; 2023 Oct; 9(10):1356-1363. PubMed ID: 37535388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal Cancer.
    Iwamoto S; Maeda H; Hazama S; Oba K; Okayama N; Suehiro Y; Yamasaki T; Suzuki N; Nagano H; Sakamoto J; Mishima H; Nagata N
    J Cancer; 2018; 9(22):4092-4098. PubMed ID: 30519308
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.